Avant Medical is currently developing the latest generation of its Pulse Injection technology for needle-free injection of medications. The patented products are intended for those who need to frequently self-administer medications or for use in a clinical setting by healthcare professionals. Pulse Injection uses vacuum stabilization and two-stage delivery to achieve reliable and comfortable injections. Each dose of medicine is delivered through a cassette with a nozzle component molded from BMS’ Makrolon Rx2530 polycarbonate resin. The injector provides a fluid pathway for the drug, while also generating a pulse that punctures the skin.
A number of medical device manufacturers rely on Makrolon Rx2530 polycarbonate resin. It is used for medical device applications requiring minimum color change after exposure to sterilizing doses of gamma radiation. Additionally, the material offers a combination of clarity, dimensional stability, and ease of processing. The resin also meets the requirements of the FDA-modified ISO 10993, Part 1 “Biological Evaluation of Medical Devices” for 30-day indirect blood contact applications. These factors contributed to Avant Medical’s selection of BMS’ Makrolon Rx2530 polycarbonate for this application.
“The technical staff at Bayer MaterialScience has been a great resource to call on,” said John Slate, Avant Medical VP of operations. “They know so much about their materials and are willing to spend the time and effort to ensure we have success with our end product.”